Related Experiment Videos
[Prajmalium bitartrat-induced liver damage (author's transl)]
Deutsche Medizinische Wochenschrift (1946)
|December 17, 1976
Summary
Prajmalium bitartrate can cause liver damage, evidenced by fever, abdominal pain, and elevated liver enzymes. This drug is poorly tolerated by the liver, similar to ajmalin.
Area of Science:
- Pharmacology
- Hepatology
- Clinical Medicine
Background:
- Prajmalium bitartrate is a medication used in certain clinical settings.
- The potential for drug-induced liver injury (DILI) is a significant concern in pharmacotherapy.
Purpose of the Study:
- To investigate and confirm liver damage associated with prajmalium bitartrate use.
- To compare the hepatotoxicity of prajmalium bitartrate with ajmalin.
Main Methods:
- Observational study involving five patients who developed liver injury while on prajmalium bitartrate.
- Diagnostic confirmation through drug re-exposure in affected patients.
- Biochemical monitoring, including glutamate-dehydrogenase levels.
Main Results:
- Five patients (3 male, 2 female) exhibited liver damage attributed to prajmalium bitartrate.
- Re-exposure to the drug confirmed causality in all cases.
- Symptoms included acute fever, severe upper abdominal pain, and jaundice. A notable rise in glutamate-dehydrogenase was observed upon re-exposure.
Conclusions:
- Prajmalium bitartrate is hepatotoxic and can cause significant liver injury.
- The drug's liver tolerability is comparable to ajmalin, with similar clinical, biochemical, and morphological effects.